| EN

Bicun®:Edaravone injection

Bicun®:Edaravone injection


Used to improve neurological symptoms and dysfunction of activities of daily living caused by acute cerebral infarction.

Stroke is one of the major central nervous system diseases. In China, the prevalence of stroke is expected to continue to grow at a CAGR of 4.5% from 16.6 million in 2020 to 19.8 million in 2024.

Commonly-used neuroprotective pharmaceuticals primarily include calcium channel blockers, free radical scavengers, membrane stabilizing agents, glutamate antagonists. The representative pharmaceutical of free radical scavengers is edaravone. Our Bicun® is a leading brand in this field.

In recent years, the prevalence of stroke increased year by year in China, indicating increasing market demand for relevant pharmaceuticals. Meanwhile, the restricted clinical use of neuroprotective pharmaceuticals led to a decrease in the prescription for pharmaceuticals for treatment of stroke, therefore releasing vast market potential for innovative pharmaceuticals with an intended indication of stroke. As of December 31, 2019, there were 11 pharmaceutical candidates for treatment of stroke at clinical stages or pending NDA approval in China, two of which were developed by us.